These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36810555)

  • 41. [Pathological characteristics and clinical prognosis of nodular sclerosis grade 2 of classic Hodgkin's lymphoma].
    Xue XM; Cao Z; Yuan T; Luo YY; Mu JL; Qin Y; Feng XL
    Zhonghua Zhong Liu Za Zhi; 2022 Jun; 44(6):581-586. PubMed ID: 35754234
    [No Abstract]   [Full Text] [Related]  

  • 42. Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy.
    Shin K; Jung EK; Park SJ; Jeong S; Kim IH; Lee MA
    World J Gastrointest Oncol; 2021 Aug; 13(8):915-928. PubMed ID: 34457195
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.
    Silvestri F; Fanin R; Velisig M; Barillari G; Virgolini L; Zaja F; Russo D; Baccarani M
    Tumori; 1994 Dec; 80(6):453-8. PubMed ID: 7534963
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
    J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group.
    Klimm B; Franklin J; Stein H; Eichenauer DA; Haverkamp H; Diehl V; Fuchs M; Borchmann P; Engert A
    J Clin Oncol; 2011 Oct; 29(29):3914-20. PubMed ID: 21911729
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma.
    Cortez AJ; Dulley FL; Saboya R; Mendrone Júnior A; Amigo Filho U; Coracin FL; Buccheri V; Linardi Cda C; Ruiz MA; Chamone Dde A
    Rev Bras Hematol Hemoter; 2011; 33(1):10-4. PubMed ID: 23284236
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
    Kahn ST; Flowers CR; Lechowicz MJ; Hollenbach K; Johnstone PA
    Cancer J; 2005; 11(5):425-31. PubMed ID: 16259874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
    Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
    Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma.
    Puig N; Pintilie M; Seshadri T; Al-Farsi K; Nagy T; Franke N; Tsang R; Keating A; Crump M; Kuruvilla J
    Haematologica; 2010 Sep; 95(9):1496-502. PubMed ID: 20460643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma without complete response to first-line therapy.
    Alici S; Bavbek S; Basaran M; Onat H
    Adv Ther; 2006; 23(4):534-42. PubMed ID: 17050496
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The prognostic value of tumour-associated macrophages in Non-Hodgkin's lymphoma: A systematic review and meta-analysis.
    Xu X; Li Z; Liu J; Zhu F; Wang Z; Wang J; Zhang J; Wang H; Zhai Z
    Scand J Immunol; 2020 Jan; 91(1):e12814. PubMed ID: 31419843
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
    Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive value of interim PET/CT visual interpretation in the prognosis of patients with aggressive non-Hodgkin's lymphoma.
    Liao CC; Qin YY; Tan XH; Hu JJ; Tang Q; Rong Y; Cen H; Li LQ
    Onco Targets Ther; 2017; 10():5727-5738. PubMed ID: 29238205
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
    Engert A; Plütschow A; Eich HT; Lohri A; Dörken B; Borchmann P; Berger B; Greil R; Willborn KC; Wilhelm M; Debus J; Eble MJ; Sökler M; Ho A; Rank A; Ganser A; Trümper L; Bokemeyer C; Kirchner H; Schubert J; Král Z; Fuchs M; Müller-Hermelink HK; Müller RP; Diehl V
    N Engl J Med; 2010 Aug; 363(7):640-52. PubMed ID: 20818855
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.
    Tzankov A; Meier C; Hirschmann P; Went P; Pileri SA; Dirnhofer S
    Haematologica; 2008 Feb; 93(2):193-200. PubMed ID: 18223287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Minimising chemotherapy while optimising immune therapy for paediatric nodular lymphocyte-predominant Hodgkin's lymphoma.
    Farhan R; Alqarni NS; Algiraigri AH
    J Taibah Univ Med Sci; 2020 Dec; 15(6):554-556. PubMed ID: 33318747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer.
    Chu-Yuan H; Jing P; Yi-Sheng W; He-Ping P; Hui Y; Chu-Xiong Z; Guo-Jian L; Guo-Qiang W
    BMC Cancer; 2013 Apr; 13():177. PubMed ID: 23551939
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.